Full-Time

Associate Director

Internal Communications and Engagement

Updated on 8/1/2026

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Maidenhead, UK

Hybrid

Three days on-site per week at the Maidenhead head office; travel to other CSL sites globally may be required.

Category
People & HR (1)
Required Skills
Journalism

Get referred to CSL

See people who can refer or advise you

Requirements
  • Strategic thinking with strong business and operational acumen.
  • Exceptional written, editorial and storytelling skills.
  • Strong stakeholder management and influencing capability.
  • Ability to operate effectively under pressure and with ambiguity.
  • High personal credibility, sound judgement and attention to detail.
  • A bachelor's degree or equivalent in Communications, Public Relations, Journalism or a related field is required.
  • At least 10 years of experience in internal communications, preferably within manufacturing, research and development or highly regulated environments.
  • Experience leading teams.
  • Proven experience advising senior leaders and managing communications in complex, matrixed organisations.
  • Experience in change and transformation communications, issues management and crisis preparedness.
Responsibilities
  • Develop and execute an integrated employee communications strategy aligned with Seqirus and enterprise-wide objectives.
  • Lead the development and regular review of the overarching Seqirus global communication plan for employees, incorporating aligned messaging for each global function and major manufacturing site.
  • Ensure major Seqirus functional and site-based projects and programs, annual business processes and activities, and events are effectively supported with comprehensive plans.
  • Provide end-to-end communications leadership for the Seqirus Leadership Forum, including agenda development, messaging, executive support and follow-up communications.
  • Lead the development and execution of regular Seqirus business updates, rolling messages, talking points and questions and answers for dissemination to the Seqirus Leadership Forum.
  • Lead the ongoing development and education of employee communications policies, processes and workflows, and build employee communications capabilities across the organisation.
  • Serve as the primary communications business partner to the Seqirus Head of Human Resources and the Human Resources Leadership Team, providing strategic counsel on leadership messaging, engagement, budget, change and business priorities.
  • Ensure enterprise, global and regional communication campaigns and initiatives are effectively localized to be timely, relevant and meaningful for Seqirus employees.
  • Oversee and manage Seqirus site communications leads.
  • Partner closely with Seqirus Human Resources and business leaders to drive global internal engagement initiatives that strengthen employee connection to the company’s mission and performance objectives.
  • Lead the planning and delivery of key global engagement moments, including town halls, leadership forums and visits, fireside chats and feedback mechanisms.
  • Lead communications capability-building initiatives for leaders to enhance their effectiveness as internal influencers and motivators.
  • Oversee site communications support for manufacturing and research and development locations, ensuring alignment between site leadership priorities and global Seqirus messaging.
  • Support site leadership teams in planning and delivering VIP visits, leadership engagements and key stakeholder moments to reinforce commercial, operational and reputational objectives.
  • Guide and oversee site-level public affairs, community engagement and local communications activities in coordination with Corporate and External Affairs colleagues.
  • Ensure consistent, high-quality content for audiences across CSL and Seqirus owned channels, including the intranet, enterprise platforms and employee communications tools.
  • Establish and track communications metrics and insights to continuously improve engagement and effectiveness.
  • Ensure all Human Resources content across Seqirus channels is current and that third-party-hosted profiles are accurate, compliant with brand guidelines and reinforce agreed brand positioning.
  • Travel to other company sites within CSL globally as required.
Desired Qualifications
  • Postgraduate qualifications.
  • Pharmaceutical, biotechnology or similarly regulated industry experience.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Seqirus separation can sharpen capital allocation toward higher-return plasma therapies.
  • CSL's 2030 strategy supports operational improvement across R&D, manufacturing, and patient access.
  • Global scale enables launches and line extensions across multiple therapeutic markets.

What critics are saying

  • Seqirus separation will trigger one-time costs and operational disruption during execution.
  • Plasma center closures directly reduce supply for CSL's core manufacturing pipeline.
  • Investor confidence stays fragile after CSL's sharp share-price decline and restructuring.

What makes CSL unique

  • CSL leads in plasma-derived therapies, influenza vaccines, and iron deficiency treatments.
  • Its CSL Plasma network supports one of the world's largest plasma collection systems.
  • CSL serves patients in 100+ countries through specialized biopharmaceutical businesses.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients